You are here
FDA Approves Adenosine Injection
Teva's Adenosine Injection USP is the generic equivalent of Fujisawa's Adenocard (R) Injection. This product is indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).
The brand product has annual sales of approximately $13 million.
Source: Teva Pharmaceutical Industries